Point cloud fusion instance effect. by Hongliang Zou (20707270)

Subjects:

Representative movie of the locomotion of nematodes with decreased body bending amplitudes after exposure to 3% isopropanol for 15 min. by Masahiro Tomioka (430683)

Subjects:

Supplementary Material for: Decreased Lactococcus lactis and propionic acid in feces of patients with Moyamoya disease: Possible implications of immune dysregulation by figshare admin karger (2628495)

“…Propionic acid levels were significantly lower in feces of the MMD patients compared to healthy controls (0.83 ± 0.34 mg/g in the MMD patients vs. 1.20 ± 0.55 mg/g in healthy controls, p = 0.028). Conclusion: Decreased Lactococcus lactis can result in reduced lactic acid and propionic acid levels in the feces of the patients. …”

Mendelian randomization analyses for the relevance of anti-H. pylori IgG seropositivity with risk of CHD. by Jing Wang (6206297)

Subjects:

Three essential assumptions of the Mendelian randomization study. by Jing Wang (6206297)

Subjects:

Mendelian randomization analysis of the effect of anti-H. pylori IgG seropositivity on coronary heart disease (CHD). by Jing Wang (6206297)

Subjects:

Results data from this Mendelian randomization study. by Jing Wang (6206297)

Subjects:

Forest plot for the significant MR association between four mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Subjects:

Associations of anti-H. pylori IgG seropositivity with mediators. by Jing Wang (6206297)

Subjects:

Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Subjects:

Details of the GWAS data in this study. by Jing Wang (6206297)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Subjects:

Mitigation (decreasing) scenario. by Fabio Correddu (12501799)

Changes in the neutrophil count. by Lu Yang (30847)

Subjects: